J&J’s Rybrevant Combo Gets FDA Approval as First Chemo-Free Treatment for NSCLC

Johnson & Johnson announced Tuesday that the FDA has approved Rybrevant with Lazcluze as a first-line chemotherapy-free treatment for patients with EGFR-mutated non-small cell lung cancer.